Alembic Pharma Q3 profit up 30% to ₹ 170 cr

PTI New Delhi | Updated on January 22, 2019 Published on January 22, 2019

Alembic Pharmaceuticals on Tuesday reported 30 per cent rise in consolidated net profit to ₹169.83 crore for the quarter ended December 31, 2018 mainly on account of robust sales in the US.

The company had posted a net profit of ₹ 130.60 crore in the year-ago period, Alembic Pharma said in a filing to BSE.

Consolidated revenue from operations stood at ₹1,018.15 crore in the reported quarter as against ₹ 840.02 crore in December quarter 2017.

“The growth in the quarter was attributed to a strong performance in the US and international business,” MD Pranav Amin said.

The company’s formulation as well as active pharmaceutical ingredient (API) facilities were successfully approved by USFDA during the quarter, he added.

The US business grew 42 per cent to ₹ 308 crore for the December quarter 2018 as against ₹ 218 crore in the year-ago period, it said.

Shares of Alembic Pharma closed at ₹587.80 per scrip on BSE, down 0.60 per cent from the previous close.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on January 22, 2019
This article is closed for comments.
Please Email the Editor